QBECO ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2

96. Crohn disease

---

Clinical trials : 2,400 /  Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03472690 (ClinicalTrials.gov)	June 25, 2018	8/3/2018	QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease	A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of QBECO SSI for the Induction and Maintenance of Clinical and Endoscopic Remission in Subjects With Moderate to Severe Crohn's Disease	Crohn Disease	Biological: QBECO-SSI;Other: Placebo	Qu Biologics Inc.	NULL	Terminated	18 Years	N/A	All	20	Phase 2	Canada
2	NCT01809275 (ClinicalTrials.gov)	March 2013	8/3/2013	Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease	A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease	Crohn's Disease;Inflammatory Bowel Disease	Drug: QBECO;Drug: Placebo	Qu Biologics Inc.	NULL	Completed	18 Years	N/A	Both	68	Phase 1/Phase 2	Canada